Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the accumulation of misfolded ...

ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale -- Effects seen on both daily function ...

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...

New research suggests that tubulin may help prevent the toxic protein clumps associated with Alzheimer’s and Parkinson’s ...

Kisspeptin‑10 (KP‑10) is a short, bioactive cleavage product of the KiSS1 precursor peptide that has gained prominence as a ...

This review argues that neurodegeneration is shaped not only by toxic protein buildup but also by immune signaling, with ...

The damage from smoking has long been traced through the lungs, heart, and blood vessels. But another pathway may be helping ...

The correlation between smoking and neurodegeneration is well-documented, with one study from 2011 finding that heavy smoking in midlife was associated with a greater than 100% increase in risk of ...

Gut-targeted interventions are promising adjuncts to conventional Parkinson's therapy, improving patients' quality of life. Changes in the gut microbiome may influence inflammation, α-synuclein ...

Can targeting α-synuclein slow the course of Parkinson’s disease? Despite years of trying, success has eluded scientists thus far. At the AD/PD conference, held March 17-21 in Copenhagen, Denmark, ...

Multiple system atrophy (MSA) is an adult-onset, rapidly progressive neurodegenerative disorder characterised by the aggregation of α-synuclein in oligodendroglial cytoplasmatic inclusions.1 ...